---
title: Utilizing the Michigan Neuropathy Screening Instrument for Early Detection of Diabetic Neuropathy
nct_id: NCT06514846
overall_status: RECRUITING
sponsor: Sohag University
study_type: OBSERVATIONAL
primary_condition: Diabetic Polyneuropathy
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06514846.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06514846"
ct_last_update_post_date: 2024-07-30
last_seen_at: "2026-05-12T07:01:10.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Utilizing the Michigan Neuropathy Screening Instrument for Early Detection of Diabetic Neuropathy

**Official Title:** Utilizing the Michigan Neuropathy Screening Instrument, Routine Nerve Conduction Study (NCS), and Nerve Ultrasound for Early Detection of Diabetic Neuropathy

**NCT ID:** [NCT06514846](https://clinicaltrials.gov/study/NCT06514846)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Sohag University
- **Conditions:** Diabetic Polyneuropathy
- **Start Date:** 2023-06-01
- **Completion Date:** 2025-06-01
- **CT.gov Last Update:** 2024-07-30

## Brief Summary

The study aims to Compare the diagnostic accuracy of the Michigan Neuropathy Screening Instrument (MNSI) (using MNS questionnaire, ,Inspection, vibratory sensation, Ankle reflexes Exam, 10 g monofilament needle examination), routine NCS, and the U/S of the median, posterior tibial, and sural nerves in identifying diabetic peripheral neuropathy in patients recently diagnosed with type 2 diabetes.

## Eligibility

- **Minimum age:** 33 Years
- **Maximum age:** 65 Years
- **Sex:** ALL

```
Inclusion Criteria:

* ü Age: 30-55 y

ü Type of diabetes: Type 2

ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria

Exclusion Criteria:

* Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.
```

## Arms

- **Patients Group** — Study Population:

Place of study: Participants will be recruited from the diabetes clinic, Sohag university hospital.

Type of the study: Cross-Sectional Comparative study.

Patients:

v Study group: participants of the study will meet the following criteria:

Ø Inclusion criteria:

ü Age: 30-55 y

ü Type of diabetes: Type 2

ü Duration of diabetes: Within 1 Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria

ü Gender: Both males \& females

Ø Exclusion criteria:

Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.

## Primary Outcomes

- **Early detection of Diabetic Neuropathy** _(time frame: Searching in patients diagnosed within 1 year or less)_ — Utilizing the Michigan Neuropathy Screening Instrument, routine nerve conduction study, and nerve ultrasound for early detection of Diabetic Neuropathy

## Locations (1)

- Faculty of medecine Sohag university, Sohag, Egypt — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.faculty of medecine sohag university|sohag||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06514846.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06514846*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*